{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:09:50Z","timestamp":1787836190734,"version":"build-2784847793"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hypertension is a major global health burden and a leading driver of cardiovascular disease, yet reliable blood-based biomarkers for early disease are still limited. We combined plasma proteomics with explainable machine learning to identify circulating proteins associated with stage 1 hypertension in the Qatar Biobank. Proteomic profiles from 778 participants (554 controls and 224 stage 1 hypertension cases) were analyzed; 1305 proteins were tested for differential expression with adjustment for age and sex, and top features were prioritized before training predictive models. Among the evaluated classifiers, CatBoost performed best (AUROC\u2009=\u20090.7985), and SHapley Additive exPlanations were used to interpret the model. We identified 36 proteins significantly associated with hypertension and observed a characteristic pattern featuring lower Renin, sRAGE, ghrelin, and IL-1RAcP, and higher TFPI, QORL1, HSP70, and C5a in hypertensive individuals. Pathway and network analyses implicated processes related to oxidative stress and vascular function. Together, these results demonstrate Renin, TFPI, sRAGE, QORL1, ghrelin, HSP70, IL-1RAcP, and C5a as candidate circulating biomarkers for hypertension and illustrate the value of explainable AI for translating proteomic signals into potentially clinically interpretable candidates, pending validation in independent and diverse cohorts.<\/jats:p>","DOI":"10.1038\/s41371-026-01134-9","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T06:05:16Z","timestamp":1776837916000},"page":"465-474","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Precision biomarker discovery in hypertension through explainable AI and proteomics"],"prefix":"10.1038","volume":"40","author":[{"given":"Karthik","family":"Sekaran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8838-6638","authenticated-orcid":false,"given":"Hatem","family":"Zayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"1134_CR1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ajem.2024.09.042","volume":"86","author":"A Farkas","year":"2024","unstructured":"Farkas A, Turner T, Sherman K, Pavlic A. Implementation of a clinical pathway for the evaluation of asymptomatic hypertension in the emergency department. Am J Emerg Med. 2024;86:37\u201340.","journal-title":"Am J Emerg Med"},{"key":"1134_CR2","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s41569-021-00559-8","volume":"18","author":"B Zhou","year":"2021","unstructured":"Zhou B, Perel P, Mensah GA, Ezzati M. Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension. Nature Reviews Cardiology. 2021;18:785\u2013802.","journal-title":"Nature Reviews Cardiology"},{"key":"1134_CR3","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s11906-023-01253-5","volume":"25","author":"F Ribeiro","year":"2023","unstructured":"Ribeiro F, Teixeira M, Alves AJ, Sherwood A, Blumenthal JA. Lifestyle medicine as a treatment for resistant hypertension. Curr Hypertens Rep. 2023;25:313\u201328.","journal-title":"Curr Hypertens Rep"},{"key":"1134_CR4","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41371-022-00789-4","volume":"37","author":"Z Azizi","year":"2023","unstructured":"Azizi Z, Alipour P, Raparelli V, Norris CM, Pilote L. The role of sex and gender in hypertension. J Hum Hypertens. 2023;37:589\u201395.","journal-title":"J Hum Hypertens"},{"key":"1134_CR5","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1111\/jch.14381","volume":"23","author":"W Zhao","year":"2021","unstructured":"Zhao W, Mo L, Pang Y. Hypertension in adolescents: The role of obesity and family history. The Journal of Clinical Hypertension. 2021;23:2065\u201370.","journal-title":"The Journal of Clinical Hypertension"},{"key":"1134_CR6","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.cjca.2015.02.008","volume":"31","author":"AC Montezano","year":"2015","unstructured":"Montezano AC, Dulak-Lis M, Tsiropoulou S, Harvey A, Briones AM, Touyz RM. Oxidative stress and human hypertension: vascular mechanisms, biomarkers, and novel therapies. Canadian Journal of Cardiology. 2015;31:631\u201341.","journal-title":"Canadian Journal of Cardiology"},{"key":"1134_CR7","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.numecd.2020.11.023","volume":"31","author":"Y Deng","year":"2021","unstructured":"Deng Y, Huang C, Su J, Pan CW, Ke C. Identification of biomarkers for essential hypertension based on metabolomics. Nutr Metab Cardiovasc Dis. 2021;31:382\u201395.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"1134_CR8","doi-asserted-by":"publisher","unstructured":"Shere A, Eletta O, Goyal H. Circulating blood biomarkers in essential hypertension: a literature review. J Lab Precis Med. 2017;2. https:\/\/doi.org\/10.21037\/jlpm.2017.12.06.","DOI":"10.21037\/jlpm.2017.12.06"},{"key":"1134_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2024.176584","volume":"972","author":"P Golmei","year":"2024","unstructured":"Golmei P, Srivastava S, Kumar S. Single nucleotide polymorphism-based biomarker in primary hypertension. Eur J Pharmacol. 2024;972:176584.","journal-title":"Eur J Pharmacol"},{"key":"1134_CR10","doi-asserted-by":"publisher","first-page":"104243","DOI":"10.1016\/j.ebiom.2022.104243","volume":"84","author":"P Louca","year":"2022","unstructured":"Louca P, Tran TQ, Toit CD, Christofidou P, Spector TD, Mangino M, et al. Machine learning integration of multimodal data identifies key features of blood pressure regulation. EBioMedicine. 2022;84:104243.","journal-title":"EBioMedicine"},{"key":"1134_CR11","doi-asserted-by":"publisher","first-page":"4896","DOI":"10.3390\/ijms25094896","volume":"25","author":"S Al Ashmar","year":"2024","unstructured":"Al Ashmar S, Anlar GG, Krzyslak H, Djouhri L, Kamareddine L, Pedersen S, et al. Proteomic analysis of prehypertensive and hypertensive patients: exploring the role of the actin cytoskeleton. Int J Mol Sci. 2024;25:4896.","journal-title":"Int J Mol Sci"},{"key":"1134_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12014-024-09519-z","volume":"22","author":"RS Aldisi","year":"2025","unstructured":"Aldisi RS, Alsamman AM, Krawitz P, Maj C, Zayed H. Identification of novel proteomic biomarkers for hypertension: a targeted approach for precision medicine. Clin Proteomics. 2025;22:7.","journal-title":"Clin Proteomics"},{"key":"1134_CR13","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1093\/aje\/kwz084","volume":"188","author":"A Al Thani","year":"2019","unstructured":"Al Thani A, Fthenou E, Paparrodopoulos S, Al Marri A, Shi Z, Qafoud F, et al. Qatar biobank cohort study: study design and first results. Am J Epidemiol. 2019;188:1420\u201333.","journal-title":"Am J Epidemiol"},{"key":"1134_CR14","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.tcm.2019.05.003","volume":"30","author":"JM Flack","year":"2020","unstructured":"Flack JM, Adekola B. Blood pressure and the new ACC\/AHA hypertension guidelines. Trends Cardiovasc Med. 2020;30:160\u20134.","journal-title":"Trends Cardiovasc Med"},{"key":"1134_CR15","unstructured":"Lundberg SM, Lee SI. A unified approach to interpreting model predictions. Adv neural inf process syst. 2017;30. https:\/\/proceedings.neurips.cc\/paper\/2017\/hash\/8a20a8621978632d76c43dfd28b67767-Abstract.html."},{"key":"1134_CR16","doi-asserted-by":"publisher","first-page":"D730","DOI":"10.1093\/nar\/gkae1113","volume":"53","author":"D Szklarczyk","year":"2025","unstructured":"Szklarczyk D, Nastou K, Koutrouli M, Kirsch R, Mehryary F, Hachilif R, et al. The STRING database in 2025: protein networks with directionality of regulation. Nucleic Acids Res. 2025;53:D730\u20137.","journal-title":"Nucleic Acids Res"},{"key":"1134_CR17","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/2042-6410-3-7","volume":"3","author":"K Sandberg","year":"2012","unstructured":"Sandberg K, Ji H. Sex differences in primary hypertension. Biol Sex Differ. 2012;3:7.","journal-title":"Biol Sex Differ"},{"key":"1134_CR18","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1161\/01.HYP.37.5.1199","volume":"37","author":"JF Reckelhoff","year":"2001","unstructured":"Reckelhoff JF. Gender differences in the regulation of blood pressure. Hypertension. 2001;37:1199\u2013208.","journal-title":"Hypertension"},{"key":"1134_CR19","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1053\/j.ackd.2014.11.004","volume":"22","author":"RM Carey","year":"2015","unstructured":"Carey RM. The intrarenal renin-angiotensin system in hypertension. Adv Chronic Kidney Dis. 2015;22:204\u201310.","journal-title":"Adv Chronic Kidney Dis"},{"key":"1134_CR20","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1093\/ajh\/hpv122","volume":"29","author":"R Uiterwijk","year":"2016","unstructured":"Uiterwijk R, Huijts M, Staals J, Rouhl RP, De Leeuw PW, Kroon AA, et al. Endothelial activation is associated with cognitive performance in patients with hypertension. Am J Hypertens. 2016;29:464\u20139.","journal-title":"Am J Hypertens"},{"key":"1134_CR21","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s11906-022-01212-6","volume":"24","author":"GF Silva","year":"2022","unstructured":"Silva GF, Fagundes TP, Teixeira BC, Chiavegatto Filho AD. Machine learning for hypertension prediction: a systematic review. Curr Hypertens Rep. 2022;24:523\u201333.","journal-title":"Curr Hypertens Rep"},{"key":"1134_CR22","doi-asserted-by":"publisher","first-page":"64","DOI":"10.2174\/0115734021349254250224074832","volume":"21","author":"Deepshikha","year":"2025","unstructured":"Deepshikha, Mathur, Monika P, Jhawat V, Shekhar S, Dutt R, et al. An overview of hypertension: pathophysiology, risk factors, and modern management. Current hypertension reviews. 2025;21:64\u201381.","journal-title":"Current hypertension reviews"},{"key":"1134_CR23","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1093\/cvr\/cvae046","volume":"120","author":"M Mulholland","year":"2024","unstructured":"Mulholland M, Depuydt MA, Jakobsson G, Ljungcrantz I, Grentzmann A, To F, et al. Interleukin-1 receptor accessory protein blockade limits the development of atherosclerosis and reduces plaque inflammation. Cardiovasc Res. 2024;120:581\u201395.","journal-title":"Cardiovasc Res"},{"key":"1134_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00395-015-0520-7","volume":"111","author":"MV Cannon","year":"2016","unstructured":"Cannon MV, van Gilst WH, de Boer RA. Emerging role of liver X receptors in cardiac pathophysiology and heart failure. Basic Res Cardiol. 2016;111:3.","journal-title":"Basic Res Cardiol"},{"key":"1134_CR25","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41392-023-01430-7","volume":"8","author":"J Ma","year":"2023","unstructured":"Ma J, Li Y, Yang X, Liu K, Zhang X, Zuo X, et al. Signaling pathways in vascular function and hypertension: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther. 2023;8:168.","journal-title":"Signal Transduct Target Ther"},{"key":"1134_CR26","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s12013-021-01010-y","volume":"79","author":"Y Ravi","year":"2021","unstructured":"Ravi Y, Sai-Sudhakar CB, Kuppusamy P. PTEN as a therapeutic target in pulmonary hypertension secondary to left-heart failure: effect of HO-3867 and supplemental oxygenation. Cell Biochem Biophys. 2021;79:593\u2013607.","journal-title":"Cell Biochem Biophys"},{"key":"1134_CR27","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/S0895-7061(03)00847-1","volume":"16","author":"PJ Lijnen","year":"2003","unstructured":"Lijnen PJ, Petrov VV, Fagard RH. Association between transforming growth factor-\u03b2 and hypertension. Am J Hypertens. 2003;16:604\u201311.","journal-title":"Am J Hypertens"},{"key":"1134_CR28","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1161\/STROKEAHA.117.017370","volume":"48","author":"Y Li","year":"2017","unstructured":"Li Y, Shen XZ, Li L, Zhao TV, Bernstein KE, Johnson AK, et al. Brain transforming growth factor-\u03b2 resists hypertension via regulating microglial activation. Stroke. 2017;48:2557\u201364.","journal-title":"Stroke"},{"key":"1134_CR29","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1016\/j.jacbts.2024.04.005","volume":"9","author":"C Becher","year":"2024","unstructured":"Becher C, Wits M, de Man FS, Sanchez-Duffhues G, Goumans MJ. Targeting soluble TGF-\u03b2 factors: advances in precision therapy for pulmonary arterial hypertension. Basic to Translational Science. 2024;9:1360\u201374.","journal-title":"Basic to Translational Science"},{"key":"1134_CR30","doi-asserted-by":"publisher","first-page":"9854","DOI":"10.1074\/jbc.RA118.002540","volume":"293","author":"RB Kasetti","year":"2018","unstructured":"Kasetti RB, Maddineni P, Patel PD, Searby C, Sheffield VC, Zode GS. Transforming growth factor \u03b22 (TGF\u03b22) signaling plays a key role in glucocorticoid-induced ocular hypertension. Journal of Biological Chemistry. 2018;293:9854\u201368.","journal-title":"Journal of Biological Chemistry"},{"key":"1134_CR31","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1055\/a-2024-0708","volume":"55","author":"J Shi","year":"2023","unstructured":"Shi J, Wei D, Wang L, Xu Q, Wang J, Ma C, et al. Serum progesterone is negatively associated with hypertension and blood pressure indicators among men and postmenopausal women. Horm Metab Res. 2023;55:273\u201383.","journal-title":"Horm Metab Res"},{"key":"1134_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.905504","volume":"9","author":"T Tasi\u0107","year":"2022","unstructured":"Tasi\u0107 T, Tadi\u0107 M, Lozi\u0107 M. Hypertension in women. Front Cardiovasc Med. 2022;9:905504.","journal-title":"Front Cardiovasc Med"},{"key":"1134_CR33","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1161\/01.HYP.37.1.142","volume":"37","author":"M Barbagallo","year":"2001","unstructured":"Barbagallo M, Dominguez LJ, Licata G, Shan J, Bing L, Karpinski E, et al. Vascular effects of progesterone: role of cellular calcium regulation. Hypertension. 2001;37:142\u20137.","journal-title":"Hypertension"},{"key":"1134_CR34","doi-asserted-by":"publisher","first-page":"5190","DOI":"10.1523\/JNEUROSCI.0164-21.2021","volume":"41","author":"TA Milner","year":"2021","unstructured":"Milner TA, Contoreggi NH, Yu F, Johnson MA, Wang G, Woods C, et al. Estrogen receptor \u03b2 contributes to both hypertension and hypothalamic plasticity in a mouse model of peri-menopause. Journal of Neuroscience. 2021;41:5190\u2013205.","journal-title":"Journal of Neuroscience"},{"key":"1134_CR35","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1152\/physrev.00041.2022","volume":"104","author":"ER Drury","year":"2023","unstructured":"Drury ER, Wu J, Gigliotti JC, Le TH. Sex differences in blood pressure regulation and hypertension: renal, hemodynamic, and hormonal mechanisms. Physiol Rev. 2023;104:199\u2013251.","journal-title":"Physiol Rev"},{"key":"1134_CR36","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13075-024-03267-z","volume":"26","author":"J Huang","year":"2024","unstructured":"Huang J, Zhu H, Liu S, Li M, Li Y, Luo H, et al. Protein profiling in systemic sclerosis patients with different pulmonary complications using proteomic antibody microarray. Arthritis Res Ther. 2024;26:29.","journal-title":"Arthritis Res Ther"},{"key":"1134_CR37","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s12018-015-9189-6","volume":"13","author":"J Tamargo","year":"2015","unstructured":"Tamargo J, Caballero R, Delp\u00f3n E. The renin\u2013angiotensin system and bone. Clinical Reviews in Bone and Mineral Metabolism. 2015;13:125\u201348.","journal-title":"Clinical Reviews in Bone and Mineral Metabolism"},{"key":"1134_CR38","unstructured":"Fountain JH, Kaur J, Lappin SL. Physiology, renin angiotensin system. 2017. https:\/\/europepmc.org\/article\/nbk\/nbk470410."},{"key":"1134_CR39","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s40292-023-00618-w","volume":"31","author":"Parra","year":"2024","unstructured":"Parra, Ram\u00edrez, Mart\u00edn P, Rojas-Marcos, Paja P, Fano, et al. Renin as a biomarker to guide medical treatment in primary aldosteronism patients. findings from the SPAIN-ALDO registry. High Blood Pressure & Cardiovascular Prevention. 2024;31:43\u201353.","journal-title":"High Blood Pressure & Cardiovascular Prevention"},{"key":"1134_CR40","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1210\/endrev\/bnad024","volume":"45","author":"GL Hundemer","year":"2024","unstructured":"Hundemer GL, Leung AA, Kline GA, Brown JM, Turcu AF, Vaidya A. Biomarkers to guide medical therapy in primary aldosteronism. Endocr Rev. 2024;45:69\u201394.","journal-title":"Endocr Rev"},{"key":"1134_CR41","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.numecd.2011.12.006","volume":"22","author":"M Volpe","year":"2012","unstructured":"Volpe M, Battistoni A, Chin D, Rubattu S, Tocci G. Renin as a biomarker of cardiovascular disease in clinical practice. Nutr Metab Cardiovasc Dis. 2012;22:312\u20137.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"1134_CR42","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1097\/MNH.0b013e32835623aa","volume":"21","author":"AJ Danser","year":"2012","unstructured":"Danser AJ. Renin and prorenin as biomarkers in hypertension. Curr Opin Nephrol Hypertens. 2012;21:508\u201314.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"1134_CR43","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1093\/ajh\/hpz022","volume":"32","author":"M Mehanna","year":"2019","unstructured":"Mehanna M, Wang Z, Gong Y, McDonough CW, Beitelshees AL, Gums JG, et al. Plasma renin activity is a predictive biomarker of blood pressure response in European but not in African Americans with uncomplicated hypertension. Am J Hypertens. 2019;32:668\u201375.","journal-title":"Am J Hypertens"},{"key":"1134_CR44","doi-asserted-by":"publisher","first-page":"728","DOI":"10.4103\/2230-8210.100665","volume":"16","author":"M Sahay","year":"2012","unstructured":"Sahay M, Sahay RK. Low renin hypertension. Indian J Endocrinol Metab. 2012;16:728\u201339.","journal-title":"Indian J Endocrinol Metab"},{"key":"1134_CR45","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1161\/HYPERTENSIONAHA.124.23385","volume":"81","author":"SS Shah","year":"2024","unstructured":"Shah SS, Fuller PJ, Young MJ, Yang J. Update on low-renin hypertension: current understanding and future direction. Hypertension. 2024;81:2038\u201348.","journal-title":"Hypertension"},{"key":"1134_CR46","doi-asserted-by":"publisher","first-page":"101399","DOI":"10.1016\/j.beem.2020.101399","volume":"34","author":"F Buffolo","year":"2020","unstructured":"Buffolo F, Monticone S, Pecori A, Pieroni J, Losano I, Cavaglia G, et al. The spectrum of low-renin hypertension. Best Practice & Research Clinical Endocrinology & Metabolism. 2020;34:101399.","journal-title":"Best Practice & Research Clinical Endocrinology & Metabolism"},{"key":"1134_CR47","doi-asserted-by":"publisher","first-page":"bvae113","DOI":"10.1210\/jendso\/bvae113","volume":"8","author":"SS Shah","year":"2024","unstructured":"Shah SS, Libianto R, Gwini SM, Rusell G, Young MJ, Fuller PJ, et al. Prevalence and characteristics of low-renin hypertension in a primary care population. J Endocr Soc. 2024;8:bvae113.","journal-title":"J Endocr Soc"},{"key":"1134_CR48","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.placenta.2021.01.018","volume":"105","author":"TM MacDonald","year":"2021","unstructured":"MacDonald TM, Tong S, Myers J, Cannon P, Nguyen TV, Keenan E, et al. Circulating tissue factor pathway inhibitor (TFPI) is increased preceding preeclampsia diagnosis and in established preeclampsia. Placenta. 2021;105:32\u201340.","journal-title":"Placenta"},{"key":"1134_CR49","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1002\/clc.4960190706","volume":"19","author":"R Altman","year":"1996","unstructured":"Altman R, Scazziota A, Rouvier J, Gurfinkei E, Favaloro R, Perrone S, et al. Coagulation and fibrinolytic parameters in patients with pulmonary hypertension. Clin Cardiol. 1996;19:549\u201354.","journal-title":"Clin Cardiol"},{"key":"1134_CR50","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/S0895-7061(99)00145-4","volume":"12","author":"Y Erdem","year":"1999","unstructured":"Erdem Y, Usalan C, Haznedaro\u011flu \u00cdC, Altun B, Arici M, Yasavul \u00dc, et al. Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension. Am J Hypertens. 1999;12:1071\u20136.","journal-title":"Am J Hypertens"},{"key":"1134_CR51","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.ijgo.2006.07.014","volume":"95","author":"AA Gader","year":"2006","unstructured":"Gader AA, Al-Mishari AA, Awadalla SA, Buyuomi NM, Khashoggi T, Al-Hakeem M. Total and free tissue factor pathway inhibitor in pregnancy hypertension. International Journal of Gynecology & Obstetrics. 2006;95:248\u201353.","journal-title":"International Journal of Gynecology & Obstetrics"},{"key":"1134_CR52","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1097\/01.hjh.0000177535.45785.64","volume":"23","author":"D Geroldi","year":"2005","unstructured":"Geroldi D, Falcone C, Emanuele E, D\u2019Angelo A, Calcagnino M, Buzzi MP, et al. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J Hypertens. 2005;23:1725\u20139.","journal-title":"J Hypertens"},{"key":"1134_CR53","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12933-019-0821-5","volume":"18","author":"AM Maresca","year":"2019","unstructured":"Maresca AM, Guasti L, Bozzini S, Mongiardi C, Tandurella N, Corso R, et al. sRAGE and early signs of cardiac target organ damage in mild hypertensives. Cardiovasc Diabetol. 2019;18:17.","journal-title":"Cardiovasc Diabetol"},{"key":"1134_CR54","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/bs.acc.2023.08.005","volume":"117","author":"C Delrue","year":"2023","unstructured":"Delrue C, Delanghe JR, Speeckaert MM. The role of sRAGE in cardiovascular diseases. Adv Clin Chem. 2023;117:53\u2013102.","journal-title":"Adv Clin Chem"},{"key":"1134_CR55","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.2337\/db12-1528","volume":"62","author":"E Selvin","year":"2013","unstructured":"Selvin E, Halushka MK, Rawlings AM, Hoogeveen RC, Ballantyne CM, Coresh J, et al. sRAGE and risk of diabetes, cardiovascular disease, and death. Diabetes. 2013;62:2116\u201321.","journal-title":"Diabetes"},{"key":"1134_CR56","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.17305\/bb.2024.10111","volume":"25","author":"GG Anlar","year":"2024","unstructured":"Anlar GG, Pedersen S, Al Ashmar S, Krzyslak H, Kamareddine L, Zeidan A. Unraveling the proteomic signatures of coronary artery disease and hypercholesterolemia. Biomolecules and Biomedicine. 2024;25:1280.","journal-title":"Biomolecules and Biomedicine"},{"key":"1134_CR57","doi-asserted-by":"publisher","first-page":"A001","DOI":"10.1161\/circ.139.suppl_1.001","volume":"139","author":"L Corlin","year":"2019","unstructured":"Corlin L, Liu C, Larson MG, Vasan RS. Proteomic signatures of cardiovascular risk factors: a cross-sectional analysis of the plasma proteome in the framingham heart study. Circulation. 2019;139:A001.","journal-title":"Circulation"},{"key":"1134_CR58","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11906-015-0622-5","volume":"18","author":"Y Mao","year":"2016","unstructured":"Mao Y, Tokudome T, Kishimoto I. Ghrelin and blood pressure regulation. Curr Hypertens Rep. 2016;18:15.","journal-title":"Curr Hypertens Rep"},{"key":"1134_CR59","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.2337\/diabetes.52.10.2546","volume":"52","author":"SM Poykko","year":"2003","unstructured":"Poykko SM, Kellokoski E, Horkko S, Kauma H, Kesaniemi YA, Ukkola O. Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes. 2003;52:2546\u201353.","journal-title":"Diabetes"},{"key":"1134_CR60","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1177\/0300060514543040","volume":"42","author":"WM Wang","year":"2014","unstructured":"Wang WM, Li SM, Du FM, Zhu ZC, Zhang JC, Li YX. Ghrelin and obestatin levels in hypertensive obese patients. Journal of international medical research. 2014;42:1202\u20138.","journal-title":"Journal of international medical research"},{"key":"1134_CR61","doi-asserted-by":"publisher","first-page":"3936","DOI":"10.3760\/cma.j.issn.0366-6999.20123353","volume":"126","author":"L ZHANG","year":"2013","unstructured":"ZHANG L. Circulating ghrelin was negatively correlated with pulmonary arterial pressure in atrial septal defect patients. Chin Med J. 2013;126:3936\u20139.","journal-title":"Chin Med J"},{"key":"1134_CR62","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/CRD.0000000000000113","volume":"24","author":"BM Lilleness","year":"2016","unstructured":"Lilleness BM, Frishman WH. Ghrelin and the cardiovascular system. Cardiol Rev. 2016;24:288\u201397.","journal-title":"Cardiol Rev"},{"key":"1134_CR63","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/s41371-024-00917-2","volume":"38","author":"B Rodriguez-Iturbe","year":"2024","unstructured":"Rodriguez-Iturbe B. Environmental stress and hypertension: the disregarded role of HSP70. J Hum Hypertens. 2024;38:538\u201341.","journal-title":"J Hum Hypertens"},{"key":"1134_CR64","doi-asserted-by":"publisher","first-page":"272","DOI":"10.3390\/biom13020272","volume":"13","author":"B Rodriguez-Iturbe","year":"2023","unstructured":"Rodriguez-Iturbe B, Johnson RJ, Sanchez-Lozada LG, Pons H. HSP70 and primary arterial hypertension. Biomolecules. 2023;13:272.","journal-title":"Biomolecules"},{"key":"1134_CR65","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1007\/s12265-024-10541-7","volume":"17","author":"J Du","year":"2024","unstructured":"Du J, Yu X, Zhang W, Zhang X, Zhao H, Xu R, et al. Plasma biomarker screening based on proteomic signature of patients with resistant hypertension. Journal of Cardiovascular Translational Research. 2024;17:1286\u201394.","journal-title":"Journal of Cardiovascular Translational Research"},{"key":"1134_CR66","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12014-024-09458-9","volume":"21","author":"MA Govender","year":"2024","unstructured":"Govender MA, Stoychev SH, Brandenburg JT, Ramsay M, Fabian J, Govender IS. Proteomic insights into the pathophysiology of hypertension-associated albuminuria: Pilot study in a South African cohort. Clin Proteomics. 2024;21:15.","journal-title":"Clin Proteomics"},{"key":"1134_CR67","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1161\/HYPERTENSIONAHA.123.22614","volume":"81","author":"JS Lin","year":"2024","unstructured":"Lin JS, Petrera A, Hauck SM, M\u00fcller CL, Peters A, Thorand B. Associations of proteomics with hypertension and systolic blood pressure: KORA S4\/F4\/FF4 and KORA Age1\/Age2 Cohort Studies. Hypertension. 2024;81:1156\u201366.","journal-title":"Hypertension"},{"key":"1134_CR68","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1001\/jamacardio.2024.1397","volume":"9","author":"P Rao","year":"2024","unstructured":"Rao P, Keyes MJ, Mi MY, Barber JL, Tahir UA, Deng S, et al. Plasma proteomics of exercise blood pressure and incident hypertension. JAMA cardiology. 2024;9:713\u201322.","journal-title":"JAMA cardiology"},{"key":"1134_CR69","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.tibtech.2015.12.013","volume":"34","author":"K Yugi","year":"2016","unstructured":"Yugi K, Kubota H, Hatano A, Kuroda S. Trans-omics: how to reconstruct biochemical networks across multiple \u2018omic\u2019layers. Trends Biotechnol. 2016;34:276\u201390.","journal-title":"Trends Biotechnol"},{"key":"1134_CR70","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12175-z","volume":"24","author":"SS Liu","year":"2024","unstructured":"Liu SS, Wan QS, Lv C, Wang JK, Jiang S, Cai D, et al. Integrating trans-omics, cellular experiments and clinical validation to identify ILF2 as a diagnostic serum biomarker and therapeutic target in gastric cancer. BMC Cancer. 2024;24:465.","journal-title":"BMC Cancer"},{"key":"1134_CR71","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03320-y","volume":"20","author":"Q Chen","year":"2022","unstructured":"Chen Q, Liang X, Wu T, Jiang J, Jiang Y, Zhang S, et al. Integrative analysis of metabolomics and proteomics reveals amino acid metabolism disorder in sepsis. J Transl Med. 2022;20:123.","journal-title":"J Transl Med"}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41371-026-01134-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41371-026-01134-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41371-026-01134-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T22:02:34Z","timestamp":1781042554000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41371-026-01134-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":71,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["1134"],"URL":"https:\/\/doi.org\/10.1038\/s41371-026-01134-9","relation":{},"ISSN":["1476-5527"],"issn-type":[{"value":"1476-5527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"assertion":[{"value":"5 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethical approval was obtained from the Institutional Review Board of the Qatar Biobank (QF-QBB-RES-ACC-00095), and the study was carried out according to the Declaration of Helsinki. Written consent was obtained from all participants to share their data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}